Section

AstraZeneca crowned as Britain's first £200bn firm as push into developing new cancer drugs pays off

By Daily Mail - 3 months ago
In a boost for chief exec Pascal Soriot (pictured), as well as an army of investors, shares in the pharmaceuticals giant rose 1.1% to a record 12,920p.

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.